Welcome to Discovery Park’s newsletter for Spring 2021.
Spring is always a hopeful time, and it particularly seems to be the case this year with the roll-out of COVID-19 vaccines across the world. Our colleagues at Pfizer are of course playing an important role in vaccine and antiviral development. You can read more about the company’s ongoing work in CEO Albert Bourla’s reflections on the first year of the pandemic.
The year has started well for other tenants too, with a grant win for Psyros Diagnostics, and expansion for Transpharmation. Food safety testing company Curtis Analytics, with exciting plans for development and expansion, has joined Discovery Park as well. You can read more on our tenants and other Discovery Park developments below.
Discovery Park is focused on building a world class, world leading science park, and at the beginning of the year we reconfirmed our areas of activity. The Strategy Pillars supporting our mission are: be an Innovation Hub; Digital and Artificial Intelligence Expertise; STEM Skills and Talent Development; and building Discovery Park Manufacturing Village.
These Pillars support our Scientific Elements, where we are developing expertise based on existing activity at Discovery Park, growth potential and national importance. The Scientific Elements are Advanced therapies; Biologicals; Neuroscience, including ophthalmology; and Agritech.
The Strategy Pillars supporting our mission are: To be
We’re looking for a new Chief Business Officer to drive these exciting activities, including our new Incubator R&D facility which we expect to open at the end of the year. Please contact Marie Dale if you would like to know more about the role.
Best wishes and we hope to see you virtually or in person soon.
Mayer Schreiber, CEO
Dr Martino Picardo, Chairman
The latest on advanced therapies in PHARMALEX webinar.
For an advanced therapy, the endpoint isn’t approval – it’s making sure all the patients that need it have access on a regular basis. That was one of the take home messages from our joint webinar with Pharmalex, in which Kate Coleman updated us on ‘Challenges, Opportunities and Market Access with Advanced Therapies.
NHSEI SBRI HEALTHCARE GRANT FOR PSYROS’ RAPID, ULTRA-SENSITIVE TEST FOR HEART ATTACK MARKER
Psyros Diagnostics had great news in February with the award of a £99,400 grant by NHSEI SBRI Healthcare to advance their novel test for the heart attack marker troponin. The company is developing ultra-sensitive, ultra-fast, point of care diagnostics based on single molecule counting, and raising a £2.5m seed round to support further prototype development.
POLISH EXPANSION FOR DISCOVERY PARK-BASED SCIENCE TEAM BOOSTS EUROPEAN CONNECTIVITY FOR KENT AND UK
Neuroscience CRO Transpharmation cemented its European links with the opening of a new facility in Poland.
FAST GROWING FOOD SAFETY TESTING FIRM CURTIS ANALYTICS RELOCATES TO DISCOVERY PARK
We are delighted to welcome Dr Tanya Curtis and her team at Curtis Analytics to Discovery Park. The company is a leader in the automated detection of asparagine, a precursor of the potentially carcinogenic chemical acrylamide, in foods.
Discovery Park facilities update – Travelodge due to open at end of April 2021
We are pleased to announce that the Discovery Park Travelodge will be open on April 30 2021.
Discovery Park joins KMEP business advisory board
We are delighted to say that our CEO Mayer Schreiber has joined Kent and Medway Economic Partnership Business Advisory Board. He’ll be working with local stakeholders to drive growth in the region.
Other news from tenants
We look forward to seeing you at the following conferences. Get in touch here to book a meeting with us.
20th May 2021
22nd June 2021
For further information on future events please contact email@example.com